







CIN: L24231GJ1988PLC011652 August 09, 2022

To.

BSE Limited

Listing Compliance & Legal Regulatory Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai - 400 001

Stock Code: 543233

To,

National Stock Exchange of India Limited

Listing & Compliance

Exchange Plaza, Bandra-Kurla Complex,

Bandra East, Mumbai 400 051

Stock Symbol: CHEMCON

Dear Sir/Madam

Subject: Report of the Monitoring Agency

Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Monitoring Agency Report dated 28.07.2022 in respect of utilization of proceeds of IPO for the quarter ended June 30, 2022, issued by HDFC Bank Limited, Monitoring Agency.

This is for your information and records.

Thanking you,

Yours Sincerely,

For Chemcon Speciality Chemicals Limited

VADODARA

Shahilkumar Kapatel

Company Secretary & Compliance Officer

Membership No. A52211

Corporate Office: 9th Floor, Onyx Business Center, Akshar Chowk, Old Padra Road, Vadodara - 390 020. INDIA Tel.: +91 265 2981195/

2983754, Fax: +91 265 2983754 Email: info@cscpl.com

Regd. Office : Block No. 355-357, Manjusar - Kunpad Road, Village: Manjusar, Taluka: Savli, Dist.: Vadodara - 391 775. INDIA Tel.: +91 2667 264104



CIN: L65920MH1994PLC080618 Website: www.hdfcbank.com HDFC Bank Limited, CMS - Disbursement Team, Lodha - I Think Techno Campus, Office Floor 3, Opposite Crompton Greaves Limited, Next to Kanjurmarg Railway Station, Kanjurmarg East, Mumbai - 400 042

SCHEDULE IX

MONITORING REPORT

NAME OF THE MONITORING AGENCY: HDFC Bank Limited

MONITORING REPORT FOR THE QUARTER ENDED: JUNE 2022

Name of the Issuer: Chemcon Speciality Chemicals Limited

(a) Deviation from the objects: Not Applicable

(b) Range of Deviation*: Not applicable

Declaration:

We hereby declare that this report is based on the format as prescribed by SEBI (ICDR) Regulation, 2018, as amended. IWe further declare basis the certification issued by the statutory auditor of the company that this report provides true and fair view of the utilization of issue proceeds.

We declare that we do not have any direct / indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship / interest while monitoring and reporting the utilization of issue proceeds by the issuer.

Signature:

Name of the Authorized Person/Signing Authority: Tushar Gavankar

1.1.600

Designation of Authorized person/Signing Authority: Vice President

Seal of the Monitoring Agency:

Date: 28.07.2022

1) Issuer Details:

Name of the issuer

The names of the promoters of the issuer

: Chemcon Speciality Chemicals Limited

: KAMALKUMAR RAJENDRA AGGARWAL,

NAVDEEP NARESH GOYAL and SHUBHARANGANA GOYAL

Industry/sector to which it belongs

: Pharmaceutical Chemicals and Oil Well Completion Chemicals

2) Issue Details:

Issue Period

: 21st September, 2020 - 23rd September, 2020

Type of issue (public/rights)

: Public Issue

Type of specified securities

: Equity Shares

Issue size (in Crores)

: Fresh issue of Rs. 165 Crores

Amount Collected (₹in Crores)

: Fresh issue of Rs. 165 Crores

3) Details of the arrangement made to ensure the monitoring of issue proceeds

Particulars	Reply	Comments of Statutory Auditor Comments (if any)	Comments of the Monitoring Agency
Whether all the utilization is as per disclosure in Offer Document?	Yes/ No	Yes	NA
Whether Shareholder approval is obtained in case of material deviations# from expenditures disclosed in Offer Document?	Yes/No	NA	NA
Whether means of finance for disclosed objects of the Issue has changed?	Yes/ No	No	NA
Any major deviation observed over the earlier monitoring agency reports?	Yes/ No	No	NA
Whether all Government / Statutory approvals related to the object(s) obtained?	Yes/No	NA	NA
Whether all arrangements pertaining to technical assistance/collaboration in operation?	Yes/No	NA	NA
Any favourable events improving object(s) viability	Yes /No	No	NA
Any unfavourable events affecting object(s) viability	Yes /No	No	NA
Any other relevant information that may materially affect the decision making of the Investors	Yes /No	No	NA

- # Where material deviation may be defined to mean:
- a) Deviation in the objects or purposes for which the funds have been raised;

b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.

4) Details of object(s)s to be monitored:

i. Cost of object(s)-

Particulars	Original Cost (as per Offer Document) (Rupees in Million)	Revised Cost (Rupees in Million)	Comments of Statutory Auditor Comments (if any)
Gross Proceeds from the Fresh Issue	1,650.00	1,650.00	
(Less) Offer expenses*@	152.12	146.51	Revision in offer expense is on account of reduction in offer expenses on actual booking as compared to estimated.
Net Proceeds	1,497.88	1,503.49	

^{*} The Offer expenses is agreed to be shared in the proportion of Equity Shares sold by the Selling Shareholders and offered by the Company. The total offer expenses are INR 282.15 million (Excluding GST), out of which company's share is INR 146.51 million, (Excluding GST) (actualized in the quarter ended March 31, 2021), based on the proportion of equity shares offered by the Company.

(Rupees in Million) Revised Comments of Original Cost (as per Cost (Rupees in Statutory Sr. Prospectus) (Rupees Item Head Million) Auditor No in Million) Comments (if any) Capital expenditure towards expansion of Manufacturing Facility 410.33 410.33 To meet working capital requirements 900.00 900.00 General corporate purposes* 187.55 193.16 **Net Proceed** 1,497.88 1,503.49

ii. Proposal to finance cost overrun, if any: Not Applicable



^{*} The revision in General corporate purposes expense is on account of reduction in offer expenses as compared to estimated.

iii. Progress in the object(s)

(Rupees in Million)

	4		Amount Utilised			
Sr. No	Item Head	Net Proceeds	As at Beginning of the Quarter	During The Quarter	At the end of Quarter	Total Unutilised Amount
1	Capital expenditure towards expansion of Manufacturing Facility	410.33	410.33	0.00	410.33	0.00
2	Incremental working capital requirement	900.00	400.00	500.00	400.00	0.00
3	General Corporate Purposes	193.16	152.21	6.20	158.21	34.75
	Total	1,503. 49	962.54	506.20	1468.74	34.75

- (a) Name of the object(s): Capital expenditure requirement
- (b) Brief description of the object(s): Capital requirement of the Company
- (c) Location of the object(s) (if applicable): Not applicable
- (a) Name of the object(s): Incremental working capital
- (b) Brief description of the object(s): Incremental working capital requirement of the Company
- (c) Location of the object(s) (if applicable): Not applicable
- (a) Name of the object(s): General corporate purpose
- (b) Brief description of the object(s): General corporate expenses of the Company
- (c) Location of the object(s) (if applicable): Not applicable

iv. Deployment of unutilized Issue proceeds: INR in millions

Sr · N o	Type of Instruments where amount Invested	Amount (in Rupees Million) Invested	Maturity Date	Earnings till 30.06.2022 Amount (in Rupees Million)	Return on Investme nt (ROI %	Book Value as at 30.06.2022 (in Rupees Million) (Net of TDS)
1	Fixed deposit- HDFC Bank	20.84	12-10-2022	0.53	3.75%	21.37
2	Fixed deposit- HDFC Bank	13.91	14-10-2022	0.35	3.75%	14.26
		34.75		0.88	- X	35.63



v. Delay in implementation of the object(s) –

Object(s) Name	Completion Date		Delay (No. of days/	Comments of Statutory	
	As per Offer	Actual *	months)	Auditor	
	Document			Comments (if any)	
Incremental working capital requirement Rs. 500 Million	Fiscal 2022	Fiscal 2023	NIL	During the quarter, the company has made vendor payments through various sources including internal accruals from customers, utilization of IPO funds and working capital facilities. Direct nexus between receipts and payments made is however impracticable	
a a a	17	8	X	to ascertain	

^{*} In case of continuing object(s) please specify latest/revised estimate of completion date.

